ERBB2 and breast neoplasm: Further investigations, however, are needed to determine whether breast tumors with ERBB2 2+ or 3+ IHC score without gene amplification but with high levels of AP-2α and YY1 have a particular behaviour regarding clinical outcome and response to Herceptin treatment.